GlassScriptPhysician profile
Jitsen Chang
NPI 1295033892
$2,601.48
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,654 · 2020: $800 · 2021: $147.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,221.80 | 2019-2020 | |
| Boston Scientific Corporation | $641.62 | 2019 | |
| Amgen INC. | $140.50 | 2019 | |
| Becton, Dickinson and Company | $136.66 | 2019 | |
| Abbvie INC. | $117.25 | 2019-2021 | |
| Therapeuticsmd, INC. | $100.48 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $88.94 | 2019-2021 | |
| Convatec INC. | $50.74 | 2019 | |
| Aspira Women'S Health INC | $26.03 | 2021 | |
| Evofem Biosciences, INC. | $22.97 | 2021 | |
| Coopersurgical, INC. | $20.54 | 2019 | |
| Organon LLC | $19.18 | 2021 | |
| Lupin INC. | $14.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jitsen Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.